Triazolam (original brand name Halcion) is a central nervous system (CNS) depressant in the benzodiazepine class. It possesses pharmacological properties similar to that of other benzodiazepines, but it is generally only used as a sedative to treat severe insomnia. In addition to the hypnotic properties triazolam possesses, amnesic, anxiolytic, sedative, anticonvulsant and muscle relaxant properties are also present. Due to its short half-life, triazolam is not effective for patients that suffer from frequent awakenings or early wakening.
Triazolam was initially patented in 1970 and went on sale in the United States in 1982.
Triazolam is usually used for short-term treatment of acute insomnia including jet lag. It is an ideal benzodiazepine for this use because its fast onset of action and short half-life. It puts one to sleep for not more than 1.5 hours (approximately 1–2 hours), allowing its user to avoid morning drowsiness. Triazolam is also sometimes used as an adjuvant in medical procedures requiring anesthesia or to reduce anxiety during brief events like MRI scans. Triazolam is ineffective in maintaining sleep however, due to its short half-life with quazepam showing superiority.